Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?